Halozyme Therapeutics, Inc. (HALO)
121.84
+0.33
(+0.27%)
USD |
NASDAQ |
Oct 16, 16:00
121.37
-0.47
(-0.39%)
After-Hours: 20:00
Halozyme Therapeutics Research and Development Expense (Annual) : 81.49M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 81.49M |
| December 31, 2024 | 79.05M |
| December 31, 2023 | 76.36M |
| December 31, 2022 | 66.61M |
| December 31, 2021 | 35.67M |
| December 31, 2020 | 34.24M |
| December 31, 2019 | 123.60M |
| December 31, 2018 | 194.45M |
| December 31, 2017 | 150.64M |
| December 31, 2016 | 150.84M |
| December 31, 2015 | 93.24M |
| December 31, 2014 | 78.60M |
| December 31, 2013 | 96.64M |
| Date | Value |
|---|---|
| December 31, 2012 | 68.96M |
| December 31, 2011 | 57.56M |
| December 31, 2010 | 51.77M |
| December 31, 2009 | 56.61M |
| December 31, 2008 | 44.23M |
| December 31, 2007 | 20.55M |
| December 31, 2006 | 9.215M |
| December 31, 2005 | 10.22M |
| December 31, 2004 | 6.517M |
| December 31, 2003 | 0.00 |
| December 31, 2002 | 0.00 |
| December 31, 2001 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| AVITA Medical, Inc. | 20.84M |
| Iovance Biotherapeutics, Inc. | 300.27M |
| Merck & Co., Inc. | 12.51B |
| Incyte Corp. | 1.984B |
| Agenus, Inc. | 79.34M |